EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of National Drug Price Negotiation policy on the innovation performance of biopharmaceutical industry in China

Yulu Zhu, Jiazhen Zhu, Xingyuan Gao, Yi Sun, Hongyu Yan, Wenmin Du, Ying Wang, Xin Li

Frontiers in Public Health · 04.11.2025 · 13

DOI: 10.3389/fpubh.2025.1705030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 04.11.2025. Verfasst von Yulu Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Drug Industry, Negotiating, Drug Costs. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The National Drug Price Negotiation (NDPN) policy is a key institutional reform in China that reshaped drug market access rules. While its effects on drug prices and accessibility are well documented, evidence on firm-level innovation performance remains limited. This study evaluates the impact of the 2019 NDPN on the innovation performance of Chinese biopharmaceutical firms.

Methods

We used quarterly panel data from 96 listed biopharmaceutical firms from 2018 Q1 to 2023 Q4. A difference-in-differences (DID) model combined with propensity score matching (PSM-DID) was employed to identify causal effects. Innovation performance was measured by R&D investment, patent application count, and overall growth score, with firm- and time-fixed effects as well as financial controls included. Robustness was assessed through parallel trend and placebo tests.

Results

DID estimates show that firms with NRDL-included drugs significantly increased R&D investment (coefficient = 0.733) and patent application count (coefficient = 0.362). Overall growth score showed no short-term change. PSM-DID confirmed these findings, with R&D investment (coefficient = 0.693) and patent application count (coefficient = 0.272) both significantly improved.

Conclusion

The NDPN policy significantly enhanced firms’ innovation performance by increasing R&D investment and patent applications, though its effect on overall growth remains limited in the short term. These findings provide firm-level evidence that NDPN strengthens innovation incentives in China’s biopharmaceutical industry.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug IndustryNegotiatingDrug CostsChinaHumans

Stichwörter der Autor:innen

National Drug Price Negotiationbiopharmaceutical industrydifference-in-differences (DID)innovation performancepolicy evaluation

Autor:innen und Institutionen

  • Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, China.
  • Department of Health Policy, School of Health Policy and Management, Nanjing Medical University, Nanjing, China.
  • Department of Infection Management, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Department of Pharmacy, The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu, China.
  • Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.

Zitieren

APA

Zhu, Y., Zhu, J., Gao, X., Sun, Y., Yan, H., Du, W., Wang, Y., & Li, X. (2025). Impact of National Drug Price Negotiation policy on the innovation performance of biopharmaceutical industry in China. Frontiers in Public Health, 13. https://doi.org/10.3389/fpubh.2025.1705030

Vancouver

Zhu Y, Zhu J, Gao X, Sun Y, Yan H, Du W, et al. Impact of National Drug Price Negotiation policy on the innovation performance of biopharmaceutical industry in China. Frontiers in Public Health. 2025;13. doi:10.3389/fpubh.2025.1705030

BibTeX
@article{Zhu2025,
  author = {Zhu, Yulu and Zhu, Jiazhen and Gao, Xingyuan and Sun, Yi and Yan, Hongyu and Du, Wenmin and Wang, Ying and Li, Xin},
  title = {Impact of National Drug Price Negotiation policy on the innovation performance of biopharmaceutical industry in China},
  journal = {Frontiers in Public Health},
  year = {2025},
  volume = {13},
  doi = {10.3389/fpubh.2025.1705030}
}
Kostenlos starten →